Victor Kotsev, Author at Labiotech.eu

About

Victor Kotsev is a reporter-at-large. He does all things business, technology, and international politics, with a special focus on health and biotech. He has spent most of the 2010s covering the Balkans and the Middle East for the likes of USA Today, Globe and Mail, and Fast Company, primarily out of Istanbul.

Articles by Victor Kotsev

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […]

April 21, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

Expert Advice 24 Mar 2021

How to Negotiate a Successful Research Collaboration Agreement

Negotiating the terms of a research collaboration can be a minefield. Life sciences attorney Lori Waldron shares her extensive experience helping biotech and pharma companies negotiate agreements. Amid a dramatic increase in funding research and development in the medical biotech sector, both larger pharmaceutical companies looking to diversify their portfolios and startups looking for a […]

March 24, 2021 - 9 minutesmins - By Victor Kotsev

News and Trends 4 Mar 2021

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. Yet the pair claim to be well capitalized to weather the storm and determined to do so together. The two companies forged an unusual blockbuster agreement in 2019, valued at around €4.5B ($5.1B), […]

March 4, 2021 - 4 minutesmins - By Victor Kotsev

Industrial plant sustainability bioeconomy

News and Trends 18 Feb 2021

Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B

This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industry. The deal is the largest to date in the medical cannabinoid field. Jazz’s offer valued GW’s shares nearly 50% higher than their previous day’s close. The acquisition is expected to […]

February 18, 2021 - 6 minutesmins - By Victor Kotsev

Expert Advice 13 Jan 2021

How Much Control Should Investors Have Over Your Biotech Company?

While getting funding from a star investor can be great for business, many biotech entrepreneurs dread the possibility of investors taking control in a situation that eerily resembles a hostile takeover. But it needn’t be that way at all. Biotech founders often complain that investors, especially VCs, demand too much control over company operations. This […]

January 13, 2021 - 6 minutesmins - By Victor Kotsev

News and Trends 21 Dec 2020

Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation

Paris-based AB Science has scored a rare late-stage clinical triumph in the Alzheimer’s disease field with a drug that puts brakes on inflammation in the brain. Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s. Although the company […]

December 21, 2020 - 5 minutesmins - By Victor Kotsev

News and Trends 17 Dec 2020

Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference

Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […]

December 17, 2020 - 6 minutesmins - By Victor Kotsev

News and Trends 4 Dec 2020

EU Launches Pharma Strategy, Raising Both Hopes and Questions

The public’s response has been cautious after the European Union unveiled a pharmaceutical strategy last week designed to spur domestic innovation and the production of affordable, state-of-the-art therapies. Amid a boom in biotech funding driven by the Covid-19 pandemic, the European Commission (EC) is scrambling to bring its sometimes fragmented pharma regulatory framework up to […]

December 4, 2020 - 6 minutesmins - By Victor Kotsev

gene therapy blood disorder hemophilia b

News and Trends 27 Nov 2020

uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapy

Gene therapies for the rare blood clotting disorder hemophilia B have taken a step closer to the market as Dutch developer uniQure became the first to release interim phase III results last week. Hemophilia is an inherited disease caused by mutations to genes encoding blood clotting proteins, resulting in uncontrollable bleeds. In severe cases of […]

November 27, 2020 - 5 minutesmins - By Victor Kotsev

Expert Advice 25 Nov 2020

How to Weather Bad Press as a Biotech Company

Biomedical companies face unique challenges when it comes to media communication. Crisis communication, in particular, can make or break a company — all the more so in a sector as sensitive as healthcare. Crises can strike a biotech company at any point — the dream partner company that had shot you to fame dumps you […]

November 25, 2020 - 7 minutesmins - By Victor Kotsev

News and Trends 9 Oct 2020

2020 Chemistry Nobel Prize Awarded to CRISPR-Cas9 Pioneers

The biotech community is raving about the long-anticipated recognition of the groundbreaking CRISPR-Cas9 gene editing tool, with the Nobel Prize in Chemistry awarded to two of its leading developers this week. The Prize in Chemistry went to Emmanuelle Charpentier, Director at the Max Planck Institute for Infection Biology in Berlin, and Jennifer Doudna, a Professor […]

October 9, 2020 - 4 minutesmins - By Victor Kotsev

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Victor Kotsev

About

Articles by Victor Kotsev

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

How to Negotiate a Successful Research Collaboration Agreement

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B

How Much Control Should Investors Have Over Your Biotech Company?

Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation

Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference

EU Launches Pharma Strategy, Raising Both Hopes and Questions

uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapy

How to Weather Bad Press as a Biotech Company

2020 Chemistry Nobel Prize Awarded to CRISPR-Cas9 Pioneers

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Victor Kotsev

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!